136 related articles for article (PubMed ID: 22394368)
1. Immunocombination therapy for high-risk neuroblastoma.
Kroesen M; Lindau D; Hoogerbrugge P; Adema GJ
Immunotherapy; 2012 Feb; 4(2):163-74. PubMed ID: 22394368
[TBL] [Abstract][Full Text] [Related]
2. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
[TBL] [Abstract][Full Text] [Related]
3. Future aspects of immunotherapy and gene therapy in neuroblastoma.
Aktas S
J BUON; 2009 Sep; 14 Suppl 1():S175-9. PubMed ID: 19785063
[TBL] [Abstract][Full Text] [Related]
4. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.
Miles SA; Sandler AD
Adv Drug Deliv Rev; 2009 Mar; 61(3):275-82. PubMed ID: 19186194
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma in Turkish children: experience of a single center.
Aydn GB; Kutluk MT; Yalçn B; Büyükpamukçu M; Kale G; Varan A; Akyüz C; Senocak ME; Büyükpamukçu N
J Pediatr Hematol Oncol; 2009 Jul; 31(7):471-80. PubMed ID: 19564739
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma: What the nurse practitioner should know.
Mazur KA
J Am Acad Nurse Pract; 2010 May; 22(5):236-45. PubMed ID: 20500737
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo.
Toyoda H; Wimmer E; Cello J
Int J Oncol; 2011 Jan; 38(1):81-7. PubMed ID: 21109928
[TBL] [Abstract][Full Text] [Related]
8. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
[TBL] [Abstract][Full Text] [Related]
9. Neuroblastoma: Therapeutic strategies for a clinical enigma.
Modak S; Cheung NK
Cancer Treat Rev; 2010 Jun; 36(4):307-17. PubMed ID: 20227189
[TBL] [Abstract][Full Text] [Related]
10. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes.
Vertuani S; De Geer A; Levitsky V; Kogner P; Kiessling R; Levitskaya J
Cancer Res; 2003 Nov; 63(22):8006-13. PubMed ID: 14633733
[TBL] [Abstract][Full Text] [Related]
11. [Long-term effect of high dose chemotherapy combined with stem cell transplantation on stage IV neuroblastoma in children].
Tang SQ; Huang DS; Wang JW; Feng C; Yang G
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr; 8(2):93-6. PubMed ID: 16613697
[TBL] [Abstract][Full Text] [Related]
12. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of human neuroblastoma.
Prigione I; Corrias MV; Airoldi I; Raffaghello L; Morandi F; Bocca P; Cocco C; Ferrone S; Pistoia V
Ann N Y Acad Sci; 2004 Dec; 1028():69-80. PubMed ID: 15650233
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
15. Enhanced resection and improved survival in murine neuroblastoma (C1300-NB) after preoperative immunotherapy.
Fowler CL; Brooks SP; Squire R; Rich GA; Rossman JE; Finegold MJ; Allen JE; Cooney DR
J Pediatr Surg; 1991 Apr; 26(4):381-7; discussion 387-8. PubMed ID: 2056397
[TBL] [Abstract][Full Text] [Related]
16. Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol.
Olgun N; Kansoy S; Aksoylar S; Cetingul N; Vergin C; Oniz H; Sarialioglu F; Kantar M; Uysal K; Tuncyurek M; Kargi A; Aktas S; Bayol U; Karaca I; Arikan A; Balik E; Aktug T; Elmas N; Kovanlikaya A; Kinay M; Anacak Y; Degirmenci B; Burak Z
Pediatr Hematol Oncol; 2003; 20(3):211-8. PubMed ID: 12637217
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside].
Rousseau R; Combaret V; Yvon E; Schell M; Philip I; Puisieux A; Frappaz D; Philip T; Bergeron C
Bull Cancer; 2006 Feb; 93(2):153-61. PubMed ID: 16517413
[TBL] [Abstract][Full Text] [Related]
18. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen.
Zheng J; Kohler ME; Chen Q; Weber J; Khan J; Johnson BD; Orentas RJ
BMC Immunol; 2007 Mar; 8():4. PubMed ID: 17397536
[TBL] [Abstract][Full Text] [Related]
19. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
20. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
